Skip to main content
Top
Published in: Immunity & Ageing 1/2019

Open Access 01-12-2019 | Alzheimer's Disease | Short report

Lag-time in Alzheimer’s disease patients: a potential plasmatic oxidative stress marker associated with ApoE4 isoform

Published in: Immunity & Ageing | Issue 1/2019

Login to get access

Abstract

In the brain, Oxidative Stress (OS) contribute to structural and functional changes associated with vascular aging, such as endothelial dysfunction, extracellular matrix degradation, resulting in age-related reduced vasodilatation in response to agonists. For this reason, OS is considered a key factor in Alzheimer’s Disease (AD) development and recent evidence correlated oxidative stress with vascular lesion in the pathogenesis of AD, but the mechanism still need to be fully clarified.
The etiology of AD is still not completely understood and is influenced by several factors including Apolipoprotein E (ApoE) genotype. In particular, the Apo ε4 isoform is considered a risk factor for AD development.
This study was aimed to evaluate the possible relationship between three plasmatic OS marker and Apo ε4 carrier status. Plasmatic soluble receptor for advanced glycation end products (sRAGE) levels, plasma antioxidant total defenses (by lag-time method) and plasmatic Reactive Oxygen species (ROS) levels were evaluated in 25 AD patients and in 30 matched controls. ROS were significantly higher while plasma antioxidant total defenses and sRAGE levels were significantly lower in AD patients compared to controls. In AD patients lag-time values show a significant positive linear correlation with sRAGE levels and a (even not significant) negative correlation with ROS levels. Lag-time is significantly lower in ε4 carrier (N = 13) than in ε4 non-carrier (N = 12). Our result confirms the substantial OS in AD. Lag-time levels showed a significant positive correlation with sRAGE levels and a significant association with ε4 carrier status suggesting that plasmatic lag-time evaluation can be considered as a potential useful OS risk marker in AD.
Literature
1.
go back to reference Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer's disease--a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015 Oct;82:593–606.PubMedCrossRef Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer's disease--a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015 Oct;82:593–606.PubMedCrossRef
2.
go back to reference Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):321–30.PubMedCrossRef Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):321–30.PubMedCrossRef
3.
go back to reference Chen Q, Wang Q, Zhu J, Xiao Q, Zhang L. Reactive oxygen species: key regulators in vascular health and diseases. Br J Pharmacol. 2018 Apr;175(8):1279–92.PubMedCrossRef Chen Q, Wang Q, Zhu J, Xiao Q, Zhang L. Reactive oxygen species: key regulators in vascular health and diseases. Br J Pharmacol. 2018 Apr;175(8):1279–92.PubMedCrossRef
4.
go back to reference Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, et al. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol. 2002 Jan;12(1):21–35.PubMedCrossRef Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, et al. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol. 2002 Jan;12(1):21–35.PubMedCrossRef
5.
go back to reference Carvalho C, Moreira PI. Oxidative stress: a major player in cerebrovascular alterations associated to neurodegenerative events. Front Physiol. 2018;9:806.PubMedPubMedCentralCrossRef Carvalho C, Moreira PI. Oxidative stress: a major player in cerebrovascular alterations associated to neurodegenerative events. Front Physiol. 2018;9:806.PubMedPubMedCentralCrossRef
7.
go back to reference Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59(6):972–6.PubMedCrossRef Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59(6):972–6.PubMedCrossRef
9.
go back to reference Tamaoka A, Miyatake F, Matsuno S, Ishii K, Nagase S, Sahara N, et al. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology. 2000 Jun 27;54(12):2319–21.PubMedCrossRef Tamaoka A, Miyatake F, Matsuno S, Ishii K, Nagase S, Sahara N, et al. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology. 2000 Jun 27;54(12):2319–21.PubMedCrossRef
11.
go back to reference Trotti R, Carratelli M, Barbieri M, Micieli G, Bosone D, Rondanelli M, et al. Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica. 2001;86(1):85–91.PubMed Trotti R, Carratelli M, Barbieri M, Micieli G, Bosone D, Rondanelli M, et al. Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica. 2001;86(1):85–91.PubMed
12.
go back to reference Cervato G, Viani P, Cazzola R, Cestaro B. A fluorescence method for the determination of plasma susceptibility to lipid peroxidation. Clin Biochem. 1999 Apr;32(3):171–7.PubMedCrossRef Cervato G, Viani P, Cazzola R, Cestaro B. A fluorescence method for the determination of plasma susceptibility to lipid peroxidation. Clin Biochem. 1999 Apr;32(3):171–7.PubMedCrossRef
16.
go back to reference Cestaro B, Gandini R, Viani P, Maraffi F, Cervato G, Montalto C, et al. Fluorescence-determined kinetics of plasma high oxidability in diabetic patients. Biochem Mol Biol Int. 1994 Apr;32(5):983–94.PubMed Cestaro B, Gandini R, Viani P, Maraffi F, Cervato G, Montalto C, et al. Fluorescence-determined kinetics of plasma high oxidability in diabetic patients. Biochem Mol Biol Int. 1994 Apr;32(5):983–94.PubMed
17.
go back to reference Atamer A, Kocyigit Y, Ecder SA, Selek S, Ilhan N, Ecder T, et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol. 2008 Nov-Dec;21(6):924–30.PubMed Atamer A, Kocyigit Y, Ecder SA, Selek S, Ilhan N, Ecder T, et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol. 2008 Nov-Dec;21(6):924–30.PubMed
21.
go back to reference Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 1997;23(1):134–47.PubMedCrossRef Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 1997;23(1):134–47.PubMedCrossRef
23.
go back to reference Ajith TA, Vinodkumar P. Advanced Glycation end products: association with the pathogenesis of diseases and the current therapeutic advances. Curr Clin Pharmacol. 2016;11(2):118–27.PubMedCrossRef Ajith TA, Vinodkumar P. Advanced Glycation end products: association with the pathogenesis of diseases and the current therapeutic advances. Curr Clin Pharmacol. 2016;11(2):118–27.PubMedCrossRef
27.
go back to reference Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009 Mar;7(1):65–74.PubMedPubMedCentralCrossRef Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009 Mar;7(1):65–74.PubMedPubMedCentralCrossRef
32.
go back to reference Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006 Feb;27(2):262–9.PubMedCrossRef Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006 Feb;27(2):262–9.PubMedCrossRef
33.
go back to reference Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996 Sep;14(1):55–61.PubMedCrossRef Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996 Sep;14(1):55–61.PubMedCrossRef
34.
go back to reference Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med. 1999 Sep;27(5–6):544–53.PubMedCrossRef Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med. 1999 Sep;27(5–6):544–53.PubMedCrossRef
35.
go back to reference Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, Cohn JS, et al. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis. 2000 Feb;7(1):23–37.PubMedCrossRef Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, Cohn JS, et al. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis. 2000 Feb;7(1):23–37.PubMedCrossRef
Metadata
Title
Lag-time in Alzheimer’s disease patients: a potential plasmatic oxidative stress marker associated with ApoE4 isoform
Publication date
01-12-2019
Published in
Immunity & Ageing / Issue 1/2019
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/s12979-019-0147-x

Other articles of this Issue 1/2019

Immunity & Ageing 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.